Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Allocca, Mariangela; Chaparro, María; Gonzalez, Haidee Aleman; Bosca-Watts, Marta Maia; Palmela, Carolina; D’Amico, Ferdinando; Zacharopoulou, Eirini; Kopylov, Uri; Ellul, Pierre; Bamias, Giorgos; Ntelis, V; Lahat, Adi; Mantzaris, Gerassimos J.; Papaconstantinou, Ioannis; Κατσάνος, Κωνσταντίνος; Uspenskaya, Yulia; Christodoulou, Dimitrios; Horin, Shomron Ben; Peyrin–Biroulet, Laurent; Torres, Joana; Sebastian, Shaji; Gisbert, Javier P.; Danese, Silvio; Fiorino, Gionata

doi:10.3390/jcm9113533

Cited by 31 publications

(54 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A large multicentric Western collaborative study reported a cumulative incidence of SARS‐CoV‐2 infection in patients with IBD of 0.4% (97 out of 23879), comparable to that of the general population (0.4%), 93 thus excluding an increased or reduced risk of COVID‐19 for these patients. The authors 93 also found that corticosteroids increased the risk of hospitalization [odds ratio (OR) 7.6], whereas monoclonal antibodies therapy reduced the risk of pneumonia and hospitalization (OR 0.1 and 0.3, respectively). Taken together, these data suggest that the risk of SARS‐CoV‐2 infection of patients with IBD seems comparable to that of the general population.…”

Section: Clinical Featuresmentioning

confidence: 90%

“…91,92 A large multicentric Western collaborative study reported a cumulative incidence of SARS-CoV-2 infection in patients with IBD of 0.4% (97 out of 23879), comparable to that of the general population (0.4%), 93 thus excluding an increased or reduced risk of COVID-19 for these patients. The authors 93 also found that corticosteroids increased the risk of hospitalization [odds ratio (OR) 7.6],…”

Section: Inflammatory Bowel Diseasementioning

confidence: 98%

“…According to another hypothesis IBD patients could be protected from the infection due to higher levels of circulating ACE2 soluble receptors which bind SARS‐CoV‐2, thus competing with cell bindings and preventing or limiting the infection 91,92 . A large multicentric Western collaborative study reported a cumulative incidence of SARS‐CoV‐2 infection in patients with IBD of 0.4% (97 out of 23879), comparable to that of the general population (0.4%), 93 thus excluding an increased or reduced risk of COVID‐19 for these patients. The authors 93 also found that corticosteroids increased the risk of hospitalization [odds ratio (OR) 7.6], whereas monoclonal antibodies therapy reduced the risk of pneumonia and hospitalization (OR 0.1 and 0.3, respectively).…”

Section: Clinical Featuresmentioning

confidence: 99%

See 2 more Smart Citations

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Marasco

Lenti

Cremon

et al. 2021

Neurogastroenterology Motil

View full text Add to dashboard Cite

Health Organization reported more than 32 million cases and 995 thousands deaths from 235 countries related to this pandemic. 2 The clinical course of SARS-CoV-2 infection can span a wide range from asymptomatic to a rapidly progressing and life-threatening disease, most commonly associated with a variety of symptoms, such as fever, cough, dyspnea, pneumonia, acute respiratory distress syndrome, systemic inflammatory response syndrome, and multiple

show abstract

Section: Clinical Featuresmentioning

confidence: 90%

Section: Inflammatory Bowel Diseasementioning

confidence: 98%

Section: Clinical Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Marasco

Lenti

Cremon

et al. 2021

Neurogastroenterology Motil

View full text Add to dashboard Cite

show abstract

“…The Coronavirus Disease 19 (COVID-19) is a systemic infection caused by the new Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2), which has impacted on Health Systems, and has led to a dramatic shrinkage of the world economy [ 1 ]. The risk of COVID-19 in patients with inflammatory bowel disease (IBD) is similar to the general population [ 1 – 3 ]. In a large cohort, the cumulative incidence of SARS-CoV-2 infection in patients with IBD versus the general population was 0.406% and 0.402% cases, respectively [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

“…The risk of COVID-19 in patients with inflammatory bowel disease (IBD) is similar to the general population [ 1 – 3 ]. In a large cohort, the cumulative incidence of SARS-CoV-2 infection in patients with IBD versus the general population was 0.406% and 0.402% cases, respectively [ 1 ]. Advances in age and treatment with corticosteroids impacted negatively on the outcome of COVID-19 [ 1 ].…”

Section: Introductionmentioning

confidence: 99%

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey

2021

Self Cite

View full text Add to dashboard Cite

Background Vaccination against COVID-19 is a major public health challenge, including the community of patients with inflammatory bowel disease. Vaccination coverage is suboptimal in inflammatory bowel disease population. It is of paramount importance to ensure an effective and rapid vaccination program with the adherence of the largest number of well-informed patients. Aims We assessed the acceptance of COVID-19 vaccination among inflammatory bowel disease patients. Methods We performed a survey as part of routine practice, between January 8th and February 22nd, 2021. All consecutive adult patients followed at Nancy University Hospital for inflammatory bowel disease were included. Patients completed a self-administered, structured, paper-based questionnaire. Demographic data, medical history, knowledge, and perceptions of COVID-19 vaccination were collected. Results Among the 104 patients who responded to the survey, 57 patients (54.8%) had intent to receive the COVID-19 vaccine. Vaccine efficacy, social responsibility, herd immunity, and desire to return to normal life were associated with self-reported willingness to receive a vaccine (20.2%, 20.2%, 11.5%, and 15.4%, respectively). Unknown long-term safety, risk of adverse reaction to vaccine and concern that the vaccine is being developed too quickly were the most commonly reported reasons for non-uptake (27.9%, 15.4%, and 12.5%, respectively). Conclusion Half of the patients with inflammatory bowel disease would like to be vaccinated against SARS-CoV-2. This rate is similar to that reported in the French general population. Despite some concerns, patients with inflammatory bowel disease understood the necessity to be vaccinated against COVID-19.

show abstract

COVID-19 und chronisch-entzündliche Darmerkrankungen

Teich¹,

Stallmach

2023

Gastroenterologie

View full text Add to dashboard Cite

Die Pandemie durch die Coronavirus Disease 2019 (COVID-19) beeinflusst weiter das Leben von Patient*innen mit chronisch-entzündlichen Darmerkrankungen (CED). Umfangreiche Untersuchungen der letzten 3 Jahre ergaben, dass die allermeisten Infektionen durch „severe acute respiratory syndrome coronavirus type 2“ (SARS-CoV-2) bei CED-Patient*innen blande verlaufen. In der Regel wird die Krankheitsaktivität der CED nicht negativ beeinflusst; bei einem Teil der Patient*innen können passager gastrointestinale Symptome auftreten. Häufig eingesetzte immunmodulierende Medikamente hatten mit Ausnahme systemischer Glukokortikoide keinen Einfluss auf den Schweregrad einer COVID-19-Erkrankung und die Gesamtletalität unterschied sich nicht von der übrigen Bevölkerung. Die Impfantwort ist jedoch substanzabhängig erniedrigt. In dieser Übersichtsarbeit werden die wichtigsten Studien praxisrelevant zusammengefasst.

show abstract

Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study

Cited by 31 publications

References 15 publications

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Implications of SARS‐CoV‐2 infection for neurogastroenterology

Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients’ Survey

COVID-19 und chronisch-entzündliche Darmerkrankungen

Contact Info

Product

Resources

About